|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Generation and characterization of SCARs by clo ningand sequencing ofRAPD products:A strategy for species-specific marker development in Bamboo显示文摘 | DAS M BH ATT ACH ARYA S PAL A | | 0，，5： | 1 |
| 2 | Highperformance liquid chromatography (HPLC) analysis of phenolic compounds in berries with diode array and electrospray ionization mass spectrometric (MS) detection:Ribes species显示文摘 | M(a)(a)att(a) K R Kamal-Eldin A T(o)rr(o)nen A R | | 0，，： | 1 |
| 3 | Identification and quantification of phenolic compounds in berries of Fragaria and Rubus species (Family rosaceae)显示文摘 | M(a)(a)att(a)-Riihinen K R Kamal-Eldin A T(o)rr(o)nen A R | | 0，，： | 1 |
| 4 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 5 | Evaluation of salt tolerance of in vitro-grown grapevine rootstock varieties显示文摘 | Troncosd A Atte CM Cantos M | 1999 | Vitis1999，38，2： | 1 |
| 6 | Aortic valve myxoma显示文摘 | Ramsheyi A Deleuze P Attelis N | 1998 | J Card Surg1998，13，： | 1 |
| 7 | Acute superior mesenteric artery syndrome显示文摘 | Kaushik R Att ri A K | 2003 | Indian pediatrics2003，40，10： | 1 |
| 8 | Duodenogastvic reflux and cencer显示文摘 | Jamed P B Stephen E A Att wood | 1999 | Hepato Gastroenterol1999，4，6： | 1 |
| 9 | Rotary tube piercing study by FEM analysis: 3D simulations and experi mental results 显示文摘 | Ceretti E Giardini C Att Anasio A | 2004 | Tube & Pipe Technology2004，，34： | 1 |
| 10 | Tigerinin-IR: a potent, non-toxic insulin-releasing peptide isolated from the skin of the Asian frog, Hoplobatrachus rugulosus显示文摘 | Ojo 0 O Abdel-Wahab Y H A F|att P R | 2011 | Diabetes Obesity and Metabolism2011，13，： | 1 |
| 11 | Assessment of cutting tool condition by acoustic emission 显示文摘 | G6mez M P Hey A M D'Attelis C E | 2012 | Procedia Materials Science2012，1，： | 1 |
| 12 | Post-operative mortaLity related to waiting time for hipfracture surgery 显示文摘 | CasaLetto J A C att R | 2004 | Injury2004，35，2： | 1 |
| 13 | PGV04, an HIV-1 gpl20 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4 显示文摘 | Falkowska E Ramos A Feng Y Zhou T Moquin S Walker LM Wu X Seaman MS Wrin T Kwong PD Wy- att RT Mascola JR Poignard P Burton DR | 2012 | J Virol2012，86，8： | 1 |
| 14 | Transparent planning for biodiversity and development in the urban fringe显示文摘 | SARAH A B MATT W ASCELIN G Atte M | 2012 | Landscape and Urban Planning2012，108，： | 1 |
| 15 | Computer systems availability evaluation using a segregatedfailures mode I显示文摘 | VILKOMIR S A PARNAS D L5MENDIR ATT A VB | 2008 | Quality and Reliability Engineering In-ternational2008，24，： | 1 |
| 16 | Root to shoot communication and abscisic acid in calreticulin (CR) gene expression and salt-stresstolerance in grafted diploid potato clones显示文摘 | JAVAD S FAWZY G ATT A H | 2005 | Environmental and Experimental Botany2005，53，3： | 1 |
| 17 | Evaluation of salt tolerance of in vitro-grown ;rrape:ine rootstock varieties 显示文摘 | Tronsosd A Atte C M Cantos M | 1999 | Vitis1999，38，2： | 1 |
| 18 | Value of maternal serum unconjugatedoestriol measurement in prenatal screening for Down's syndrome显示文摘 | W ald NJ Kennard A W att Hc | 1994 | Prenat Diagn1994，14，8： | 1 |
| 19 | Identification of Fasciola Species Based onMitochondrial and Nuclear DNA Reveals the Co-Existence of Intermediate Fasciola and Fasciola gigantica in Thailand 显示文摘 | WANNASAN A K H OSIT H AR ATT AN AK OOL P CHAIWONG P | 2014 | Ex-perimental Parasitology2014，6470，： | 1 |
| 20 | Obesity is not protective against fracture in postmenopausal women:GLOW显示文摘 | Compston JE W atts N B C hapurlat R C ooper C B oonen S Greenspan S Pfeilschifter J Silverman S Díez-Pérez A Lindsay R Saag KG Netelenbos JC Gehlbach S Hooven FH Flahive J Adachi J D R ossini M Lacroix A Z Roux C S ambrook PN S iris ES Glow Investigators | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员